Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

BACKGROUND: Sunitinib is a protein tyrosine kinase-inhibitor targeting VEGFR, c-kit and PDGFR. It has been approved for the treatment of metastatic renal-cell carcinoma and gastrointestinal stromal tumors. Although it has been shown to prolong disease-free and overall survival in renal-cell carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales: Kontovinis, Loukas F, Papazisis, Konstantinos T, Touplikioti, Panagiota, Andreadis, Charalambos, Mouratidou, Despoina, Kortsaris, Alexandros H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662874/
https://www.ncbi.nlm.nih.gov/pubmed/19284623
http://dx.doi.org/10.1186/1471-2407-9-82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662874/
https://www.ncbi.nlm.nih.gov/pubmed/19284623
http://dx.doi.org/10.1186/1471-2407-9-82

Ejemplares similares